Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “ivacaftor” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 11
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 11 pipeline programs matching "ivacaftor" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

11 results for “ivacaftor” Back to intelligence hub

Search results

  1. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    16 trials
  2. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial
  3. Lumacaftor Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation

    phase 3 small molecule completed

    1 trial
  4. Tezacaftor/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    3 trials
  5. VX-661 Plus Ivacaftor Combination

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    2 trials
  6. VX-661/Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 3 small molecule completed

    1 trial
  7. Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule terminated

    1 trial
  8. Ivacaftor 150 MG

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Obstructive Pulmonary Disease

    phase 2 small molecule completed

    1 trial
  9. Ivacaftor 25 mg/75 mg

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  10. Tezacaftor/Ivacaftor + Ivacaftor

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial
  11. lumacaftor 200 mg q12h + ivacaftor 250 mg q12h

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatic Impairment

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.